Belay Diagnostics
Belay Diagnostics provides advanced genomic profiling tests, Summit™ and Vantage™, utilizing cerebrospinal fluid (CSF) for central nervous system malignancies. These liquid biopsy assays offer clinicians a validated and accurate alternative to invasive biopsies for diagnosis and treatment management. The company aims to support clinicians in achieving a higher standard of care for patients with primary and metastatic brain and spinal cord cancers.
- Biotechnology
- Healthcare Technology
Funding
Raised to date
$5.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$304K across 1 disclosed round
$304K · Grant
Announced Jul 2024
Disclosed cumulative: $304K
Reported total $5.8M
Incomplete round history. $5.4M of the $5.8M reported total isn’t matched to a known round.
Founders
Founder details are not available yet.
Product
Features
- Belay Diagnostics provides advanced genomic profiling tests, Summit™ and Vantage™, utilizing cerebrospinal fluid (CSF) for central nervous system malignancies. These liquid biopsy assays offer clinicians a validated and accurate alternative to invasive biopsies for diagnosis and treatment management. The company aims to support clinicians in achieving a higher standard of care for patients with primary and metastatic brain and spinal cord cancers.